1. Scrip
  2. >>Business
  3. >>Strategy

Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback

 
• By Joseph Haas

The Phase III failure of ampreloxetine in nOH followed disappointing Phase IIb data for izencitinib in ulcerative colitis in August. Theravance narrows focus to respiratory disease, including label expansions for Yupelri.

Business reengineering
Theravance will try an overhaul focused on respiratory disease to stay viable

Earlier this year, Theravance Biopharma Inc. was looking forward to a pair of trial readouts as potential inflection points for its pipeline of organ-selective therapies. Now, however, both of those studies have failed, and the company is undertaking a substantial restructuring that includes cutting its workforce by 75% and narrowing its R&D focus to respiratory disease, including potential label expansions for Yupelri.

Theravance announced on 15 September that ampreloxetine (TD-9855) did not hit its primary endpoint in a Phase III study in symptomatic neurogenic orthostatic hypotension (nOH). In August, the Dublin-headquartered firm reported another disappointing data readout as its gut-selective JAK inhibitor izencitinib (TD-1473), partnered with Janssen Biotech Inc., missed primary and secondary endpoints in a Phase IIb study in ulcerative colitis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.